

10030015blessing

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1997:784151 CAPLUS

DOCUMENT NUMBER: 128:53279

TITLE: Transdermal patch with good skin compatibility and storage stability

INVENTOR(S): Hirano, Munehiko; Maki, Masayoshi

PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09315957	A2	19971209	JP 1996-171579	19960528
PRIORITY APPLN. INFO.:			JP 1996-171579	19960528

AB The preparation at least contains (A) a drug-impermeable backing layer, (B) a drug-storing layer, and (C) a drug-releasing layer comprising a drug-permeable film and a pressure-sensitive adhesive layer. The drug may be follicle hormones and/or progestins for hormone replacement therapy. A release liner was coated with an adhesive composition containing **styrene-isoprene-styrene** block copolymer, an acrylic adhesive, liquid paraffin, an alicyclic saturated hydrocarbon resin tackifier, polyisobutylene, and dibutylhydroxytoluene, and covered with a porous sheet. Subsequently a composition containing estradiol was poured onto the side of the porous sheet, and the area surrounding the drug composition was heat-sealed with a backing material to give a transdermal patch. Application of the patch to arm for 72 h caused no erythema.

blessing

10030015blessing

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN

RN 50-28-2 REGISTRY

CN Estra-1,3,5(10)-triene-3,17-diol (17 $\beta$ )- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN **Estradiol (8CI)**

OTHER NAMES:

CN (+)-3,17 $\beta$ -Estradiol

CN  $\beta$ -Estradiol

CN 13 $\beta$ -Methyl-1,3,5(10)-gonatriene-3,17 $\beta$ -ol

CN 17 $\beta$ -Estradiol

CN 17 $\beta$ -Oestradiol

CN 3,17-Epidihydroxyestratriene

CN 3,17 $\beta$ -Dihydroxyestra-1,3,5(10)-triene

CN 3,17 $\beta$ -Estradiol

CN Aerodiol

CN Altrad

CN Aquadiol

CN Bardiol

CN Beta-estradiol

CN Climaderm

CN Climara

CN Compudose

CN Compudose 200

CN Compudose 365

CN Corpagen

CN Dermestril

CN Dihydrofollicular hormone

CN Dihydrofolliculin

CN Dihydromenformon

CN Dihydrotheelin

CN Dihydroxyestrin

CN Dimenformon

CN Diogyn

CN Diogynets

CN Divigel

CN E 2

CN Encore

CN Epiestriol 50

CN Estra-1,3,5(10)-triene-3,17-diol, (17 $\beta$ )-

CN Estra-1,3,5(10)-triene-3,17 $\beta$ -diol

CN Estrace

CN Estraderm

CN Estraderm TTS

CN Estraderm TTS 100

CN Estraderm TTS 50

CN Estradot

CN Estraldine

CN Estring Vaginal Ring

CN Estroclim

CN Estroclim 50

CN Estrogel

CN Estrovite

CN Evorel

CN Femanest

CN Femestral


ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for

blessing

10030015blessing

DISPLAY  
FS STEREOSEARCH  
MF C18 H24 O2  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN\*,  
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,  
CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHM,  
CSNB, DDFU, DETHERM\*, DIOGENES, DRUGU, EMBASE, GMELIN\*, HODOC\*, HSDB\*,  
IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IMSRESEARCH, IPA,  
MEDLINE, MRCK\*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT,  
PROUDDR, PS, RTECS\*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN,  
USPAT2, USPATFULL, VETU  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, WHO  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)  
DT.CA Caplus document type: Book; Conference; Dissertation; Journal; Patent;  
Report  
RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);  
FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU  
(Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT  
(Reactant or reagent); USES (Uses); NORL (No role in record)  
RLD.P Roles for non-specific derivatives from patents: ANST (Analytical  
study); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation);  
PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES  
(Uses)  
RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological  
study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU  
(Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT  
(Reactant or reagent); USES (Uses); NORL (No role in record)  
RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical  
study); BIOL (Biological study); FORM (Formation, nonpreparative); OCCU  
(Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT  
(Reactant or reagent); USES (Uses)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

52115 REFERENCES IN FILE CA (1907 TO DATE)  
869 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
52179 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
12 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

blessing

10030015blessing

blessing

10030015blessing

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN  
RN 68-22-4 REGISTRY  
CN 19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17 $\alpha$ )- (9CI) (CA INDEX  
NAME)  
OTHER CA INDEX NAMES:  
CN 19-Nor-17 $\alpha$ -pregn-4-en-20-yn-3-one, 17-hydroxy- (7CI, 8CI)  
OTHER NAMES:  
CN (17 $\alpha$ )-17-Hydroxy-19-Norpregn-4-en-20-yn-3-one  
CN 17-Hydroxy-19-nor-17 $\alpha$ -pregn-4-en-20 yn-3-one  
CN 17 $\alpha$ -Ethynyl-17 $\beta$ -hydroxy- $\Delta$ 4-estren-3-one  
CN 17 $\alpha$ -Ethynyl-19-nortestosterone  
CN 17 $\alpha$ -Ethynylestr-4-en-17 $\beta$ -ol-3-one  
CN 17 $\alpha$ -Ethynyl-17-hydroxy-4-estrene-3-one  
CN 17 $\alpha$ -Ethynyl-17-hydroxyestr-4-en-3-one  
CN 17 $\alpha$ -Ethynyl-17 $\beta$ -hydroxy-19-norandrost-4-en-3-one  
CN 17 $\alpha$ -Ethynyl-17 $\beta$ -hydroxyestr-4-en-3-one  
CN 17 $\alpha$ -Ethynyl-19-nor-androst-4-en-17 $\beta$ -ol-3-one  
CN 17 $\alpha$ -Ethynyl-19-nortestosterone  
CN 17 $\alpha$ -Ethynyl-3-oxo-4-estren-17 $\beta$ -ol  
CN 17 $\beta$ -Hydroxy-17 $\alpha$ -ethynylestr-4-en-3-one  
CN 19-Nor-17 $\alpha$ -ethynyl-17 $\beta$ -hydroxy-4-androsten-3-one  
CN 19-Nor-17 $\alpha$ -ethynylandrosten-17 $\beta$ -ol-3-one  
CN 19-Nor-17 $\alpha$ -ethynyltestosterone  
CN 19-Norandrost-4-en-3-one, 17 $\alpha$ -ethynyl-17 $\beta$ -hydroxy-  
CN 19-Nortestosterone, 17-ethynyl-  
CN Anovule  
CN Conludaf  
CN Conludag  
CN Estr-4-ene-17 $\alpha$ -ethynyl-17 $\beta$ -ol-3-one  
CN Ethynylnortestosterone  
CN Ethynylnortestosterone  
CN Gestest  
CN Menzol  
CN Micronett  
CN Micronor  
CN Micronovum  
CN Mini-Pe  
CN Mini-pill  
CN Nor-QD  
CN Noralutin  
CN Norcolut  
CN Norethindrone  
CN Norethisteron  
CN **Norethisterone**  
CN Norethynodrone  
CN Norfor  
CN Norgestin  
CN Norluten  
CN Norlutin  
CN Norluton  
CN Normapause  
CN Norpregneninolone  
CN NSC 9564  
CN Primolut N  
CN Proluteasi

blessing

10030015blessing

ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for  
DISPLAY

FS STEREOSEARCH

MF C20 H26 O2

CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS,  
CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM,  
CSNB, DDFU, DIOGENES, DRUGU, EMBASE, HSDB\*, IFICDB, IFIPAT, IFIUDB,  
IMSCOSEARCH, IPA, MEDLINE, MRCK\*, MSDS-OHS, NIOSHTIC, PHAR, PIRA, PROMT,  
PS, RTECS\*, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU  
(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

DT.CA CAplus document type: Book; Conference; Dissertation; Journal; Patent;  
Report


RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);  
PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or  
reagent); USES (Uses); NORL (No role in record)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological  
study); PREP (Preparation); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological  
study); FORM (Formation, nonpreparative); MSC (Miscellaneous); OCCU  
(Occurrence); PREP (Preparation); PROC (Process); PRP (Properties); RACT  
(Reactant or reagent); USES (Uses); NORL (No role in record)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical  
study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP  
(Preparation); PROC (Process); PRP (Properties); RACT (Reactant or  
reagent); USES (Uses)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2248 REFERENCES IN FILE CA (1907 TO DATE)  
66 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
2251 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
7 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

blessing

10030015blessing

L7 ANSWER 1 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2004:51925 USPATFULL

TITLE: Compositions for external preparations

INVENTOR(S): Maki, Masayoshi, Tashirodaikan-machi, Tosu-shi, JAPAN  
Ikeura, Yasuhiro, Tashirodaikan-machi, Tosu-shi, JAPAN

*Applicants*

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004039356	A1	20040226
APPLICATION INFO.:	US 2003-399294	A1	20030414 (10)
	WO 2001-JP7632		20010904

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2000-315179	20001016
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARDS & ANGELL, LLP, P.O. BOX 9169, BOSTON, MA, 02209	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	563	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It is intended to provide compositions for external preparations (in particular, adhesive preparations) which are excellent in the skin permeability of the active ingredient, make it possible to give a compact preparation size and exert relieved skin irritation in percutaneous preparations, etc. to be used in, for example, hormone substitution therapy. Namely, compositions for external preparation which contain a vegetable oil and polyvinyl pyrrolidone as a sorbefacient and/or a dissolution aid; and adhesive preparations containing these compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:329862 USPATFULL

TITLE: Enhanced drug delivery in transdermal systems

INVENTOR(S): Houze, David, Coconut Grove, FL, UNITED STATES  
Nguyen, Viet, Miami, FL, UNITED STATES

PATENT ASSIGNEE(S): Noven Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003232073	A1	20031218
APPLICATION INFO.:	US 2002-330281	A1	20021230 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2002-US16579, filed on 18 Jun 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007		
NUMBER OF CLAIMS:	52		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	9 Drawing Page(s)		
LINE COUNT:	1399		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

blessing

10030015blessing

AB A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a drug that includes a parent drug and a prodrug; and a pharmaceutically acceptable carrier, wherein the parent drug and prodrug are individually present in an amount sufficient for a pharmacological effect. In a preferred embodiment, the admixture includes: a therapeutically effective amount of a pharmaceutically active agent that includes a corresponding steroid and a steroid derivative; and a carrier for the pharmaceutically active agent. The steroid and the corresponding steroid derivative are present in a weight ratio of 10:1 to 1:10 steroid: corresponding steroid derivative. In a preferred embodiment ratio is 6:1 to 1:6. In a preferred embodiment, the corresponding steroid derivative is a steroid ester. In another preferred embodiment, the carrier is a polymer that includes a pressure-sensitive adhesive. In another preferred embodiment, the parent drug is an ACE inhibitor such as ramipril and the prodrug is an ACE inhibitor prodrug such as ramipril ethyl and/or methyl ester.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:219325 USPATFULL  
TITLE: Enhanced drug delivery in transdermal systems  
INVENTOR(S): Houze, David, Coconut Grove, FL, UNITED STATES  
PATENT ASSIGNEE(S): Noven Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003152615	A1	20030814
APPLICATION INFO.:	US 2002-330361	A1	20021230 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-948107, filed on 7 Sep 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-298381P	20010618 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	825	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a pharmaceutically active agent that includes a corresponding steroid and a steroid derivative; and a carrier for the pharmaceutically active agent. The steroid and the corresponding steroid derivative are present in a weight ratio of 10:1 to 1:10 steroid: corresponding steroid derivative. In a preferred embodiment ratio is 6:1 to 1:6. In a preferred embodiment, the corresponding steroid derivative is a steroid ester. In another preferred embodiment, the carrier is a polymer that includes a pressure-sensitive adhesive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

blessing



10030015blessing

L7 ANSWER 4 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:219324 USPATFULL  
TITLE: Enhanced drug delivery in transdermal systems  
INVENTOR(S): Houze, David, Coconut Grove, FL, UNITED STATES  
PATENT ASSIGNEE(S): Noven Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003152614	A1	20030814
APPLICATION INFO.:	US 2002-330360	A1	20021230 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-948107, filed on 7 Sep 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-298381P	20010618 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	825	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a pharmaceutically active agent that includes a corresponding steroid and a steroid derivative; and a carrier for the pharmaceutically active agent. The steroid and the corresponding steroid derivative are present in a weight ratio of 10:1 to 1:10 steroid: corresponding steroid derivative. In a preferred embodiment ratio is 6:1 to 1:6. In a preferred embodiment, the corresponding steroid derivative is a steroid ester. In another preferred embodiment, the carrier is a polymer that includes a pressure-sensitive adhesive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:219323 USPATFULL  
TITLE: Enhanced drug delivery in transdermal systems  
INVENTOR(S): Houze, David, Coconut Grove, FL, UNITED STATES  
PATENT ASSIGNEE(S): Noven Pharmaceuticals, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003152613	A1	20030814
APPLICATION INFO.:	US 2002-330279	A1	20021230 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-948107, filed on 7 Sep 2001, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-298381P	20010618 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW,	

blessing

10030015blessing

WASHINGTON, DC, 20007

NUMBER OF CLAIMS: 31  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 3 Drawing Page(s)  
LINE COUNT: 825

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition for transdermal administration resulting from an admixture includes: a therapeutically effective amount of a pharmaceutically active agent that includes a corresponding steroid and a steroid derivative; and a carrier for the pharmaceutically active agent. The steroid and the corresponding steroid derivative are present in a weight ratio of 10:1 to 1:10 steroid: corresponding steroid derivative. In a preferred embodiment ratio is 6:1 to 1:6. In a preferred embodiment, the corresponding steroid derivative is a steroid ester. In another preferred embodiment, the carrier is a polymer that includes a pressure-sensitive adhesive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:31334 CAPLUS  
DOCUMENT NUMBER: 134:91154  
TITLE: Adhesive preparation for percutaneous absorption  
INVENTOR(S): Maki, Masayoshi; Ikeura, Yasuhiro  
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan  
SOURCE: PCT Int. Appl., 21 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001001990	A1	20010111	WO 2000-JP4361	20000630
W: JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1197212	A1	20020417	EP 2000-942427	20000630
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: JP 1999-187415 A 19990701  
WO 2000-JP4361 W 20000630

AB The invention relates to an adhesive preparation for percutaneous absorption in which high drug permeability at a low drug concentration and satisfactory drug stability have been obtained by regulating the solubility of a drug in a base. The adhesive preparation comprises a base comprising a **styrene/isoprene/styrene** block copolymer and norethisterone contained in the base. Preferably, the drug is dissolved in the base in an amount of up to 2 weight% based on the whole base.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2000:260067 CAPLUS  
DOCUMENT NUMBER: 132:270106  
TITLE: Sorbefacients and preparations for percutaneous

blessing

10030015blessing

absorption containing the same  
INVENTOR(S): Ikeura, Yasuhiro; Maki, Masayoshi  
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan  
SOURCE: PCT Int. Appl., 26 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000021566	A1	20000420	WO 1999-JP5670	19991014
W: AU, BR, CA, CN, ID, KR, NO, SG, US, VN				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2000119195	A2	20000425	JP 1998-291851	19981014
AU 9961229	A1	20000501	AU 1999-61229	19991014
EP 1121941	A1	20010808	EP 1999-947897	19991014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: JP 1998-291851 A 19981014  
WO 1999-JP5670 W 19991014

AB The invention relates to percutaneous sorbefeacients comprising hexylene glycol and l-menthol, more particularly, percutaneous sorbefeacients for female hormones or derivs. thereof; and preps. for percutaneous absorption which comprise a **styrene/isoprene/styrene** block copolymer and/or polyisobutylene, a softener and a tackifier as the base components, hormones, in particular, follicle hormone and/or luteal hormone as the drug component and hexylene glycol and l-menthol as a sorbefeacient.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 1998:706123 CAPLUS

DOCUMENT NUMBER: 129:321217

TITLE: Base composition for percutaneous absorption and percutaneously absorbable preparation containing it

INVENTOR(S): Hirano, Munehiko; Maki, Masayoshi

PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan

SOURCE: PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9846267	A1	19981022	WO 1998-JP1745	19980416
W: AU, BR, CA, CN, ID, KR, MX, NO, PL, SG, US, VN				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9868525	A1	19981111	AU 1998-68525	19980416
AU 723018	B2	20000817		
JP 11001441	A2	19990106	JP 1998-121664	19980416

blessing

10030015blessing

EP 976405 A1 20000202 EP 1998-914050 19980416  
R: AT, CH, DE, ES, FR, GB, IT, LI, NL, SE, FI  
BR 9808594 A 20000523 BR 1998-8594 19980416  
NO 9905032 A 19991015 NO 1999-5032 19991015  
PRIORITY APPLN. INFO.: JP 1997-115254 A 19970416  
WO 1998-JP1745 W 19980416

AB A base composition for percutaneous absorption comprises a **styrene/isoprene/styrene** block copolymer, softening agent, adhesive resin, and hexylene glycol. The base composition is useful for enhancement of percutaneous absorption of hormones such as estradiol in treatment of menopause and menstruation disorders.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 10 USPATEFULL on STN

ACCESSION NUMBER: 1998:124212 USPATEFULL

TITLE: Percutaneously absorbable patch

INVENTOR(S): Hirano, Munehiko, Tsukuba, Japan  
Shinmura, Miyuki, Tsukuba, Japan  
Kojima, Masaki, Tsukuba, Japan

PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Tosu, Japan  
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5820878		19981013
	WO 9615776		19960530
APPLICATION INFO.:	US 1997-817878		19970428 (8)
	WO 1995-JP2336		19951115
			19970428 PCT 371 date
			19970428 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1994-309762	19941118
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Shelborne, Kathryn E.	
LEGAL REPRESENTATIVE:	Kubovcik & Kubovcik	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	665	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A percutaneously absorbable preparation-containing patch, wherein the preparation comprises: (1) a base comprising as essential ingredients a (A-B) n-A based elastomer wherein A is substantially a monovinyl-substituted aromatic compound polymer block, B is substantially a conjugated diolefin copolymer block, and n is an integer of 3-7, crotamiton, and a softening agent; and (2) at least two hormones, especially estrogen and luteal hormones, as active ingredients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2004 ACS on STN

blessing

10030015blessing

ACCESSION NUMBER: 1997:784151 CAPLUS  
DOCUMENT NUMBER: 128:53279  
TITLE: Transdermal patch with good skin compatibility and storage stability  
INVENTOR(S): Hirano, Munehiko; Maki, Masayoshi  
PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	----	-----	-----
JP 09315957	A2	19971209	JP 1996-171579	19960528
PRIORITY APPLN. INFO.:			JP 1996-171579	19960528

AB The preparation at least contains (A) a drug-impermeable backing layer, (B) a drug-storing layer, and (C) a drug-releasing layer comprising a drug-permeable film and a pressure-sensitive adhesive layer. The drug may be follicle hormones and/or progestins for hormone replacement therapy. A release liner was coated with an adhesive composition containing **styrene-isoprene-styrene** block copolymer, an acrylic adhesive, liquid paraffin, an alicyclic saturated hydrocarbon resin tackifier, polyisobutylene, and dibutylhydroxytoluene, and covered with a porous sheet. Subsequently a composition containing estradiol was poured onto the side of the porous sheet, and the area surrounding the drug composition was heat-sealed with a backing material to give a transdermal patch. Application of the patch to arm for 72 h caused no erythema.

blessing

10030015blessing

d his

(FILE 'HOME' ENTERED AT 17:05:05 ON 11 JUN 2004)

FILE 'REGISTRY' ENTERED AT 17:05:13 ON 11 JUN 2004

L1 1 S NORETHISTERONE/CN  
L2 1 S ESTRADIOL/CN

FILE 'CAPLUS, USPATFULL' ENTERED AT 17:06:20 ON 11 JUN 2004

L3 2497 S L1  
L4 53372 S L2  
L5 5582 S STYRENE(W) ISOPRENE(W) STYRENE  
L6 10 S L3 AND L4 AND L5  
L7 10 DUP REM L6 (0 DUPLICATES REMOVED)

blessing